• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • GPs

Q&A - Bob Long, President, CEO, Conversus Asset Management

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

Deborah Sterescu speaks to Bob Long of listed fund-of-funds Conversus Asset Management, about making a GP's track record the priority

Given the downturn in the markets, would you, as an LP, do anything differently now? What advice would you give to a first time investor?

The recent market dislocation brought to the forefront the importance of liquidity within an investment programme. While Conversus has been consistently comfortable with our liquidity position, a number of investment programmes experienced significant liquidity constraints. The typical over-commitment strategies will need to be reassessed to ensure obligations can be met.

For a first time investor looking for immediate exposure to private equity, an investment in a publicly traded fund-of-funds is an ideal option. It can provide immediate access to a diversified set of private equity funds well positioned on the j-curve. At current trading prices, investors can access our portfolio at a substantial discount to net asset value.

For those looking to invest directly, we would recommend funds run by well-established general partners that have proven their ability to make money across various phases of the economic cycle by making operational improvements to their portfolio companies and growing cash flow. We are great believers in the persistency of performance by private equity GPs and these are the types of funds that typify our portfolio.

What would you say is the biggest change in terms of how a GP treats its LPs now?

The relationship between GP and LP continues to evolve, and the balance of negotiating power swings with the market. Clearly, GPs have responded to investor demand for greater transparency in the portfolios being built and managed. This they have done through investing in IR resources, greater use of technology to communicate messages and expanding the information about underlying portfolio performance.

Often, the strength of the fundraising market brings changes to the economic balance in the partnership terms. Today, the balance has shifted to LPs who are more frequently seeking better terms from GPs and often succeeding. We have witnessed a closer alignment of interest in transaction fees, (which seem to be migrating toward, at minimum, an 80/20 split), disappearance of premium carry arrangements, stronger clawback provisions, more pervasive LP rights to change partnership management, agreement that time diversification when investing is a valuable portfolio tool, and an even greater level of disclosure.

The recently released ILPA Private Equity Principals will be a foundation for many of these forthcoming negotiations.

What is more relevant when assessing the merit of a GP, their track record or the current underlying portfolio?

Understanding how the GP has invested through economic cycles is an important element of assessing quality. We are looking for consistency of strategy, cohesion of the partnership and its decision making ability, and observing the value-add brought to their investments over time. So, while performance of the current portfolio can be insightful, gaining confidence that success can be consistently repeated is a priority.

What is the best indication of the true skill of a GP - cash in versus out in the last five years, or current performance (realised and unrealised)?

Five years in the context of private equity is a relatively short period of time. However, I do believe that the GP needs to strike the right balance between cash returns and IRR. A strong cash return generated over 15 years may not be competitive with other asset classes into which LPs have the option to invest. Particularly in the current market, however, understanding the value a GP has brought to its investments in the current portfolio to both weather the storm as well as position for future success, will dictate if these GPs will themselves succeed when returning to market for that next fund.

Do you see the typical 10+2 year fund structure changing at all in the future?

Private equity is a long-term asset class, one that takes time to source, close, improve and finally exit investment opportunities. As a consequence, I anticipate that the traditional 10 + 2 year fund structure will survive. Where you might see a change is in the investment period. In recent years the investment period in many fund documents has been lengthened to 5-6 years. I could see the investment period reverting back to the more historical standard of 4-5 years.

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • GPs
  • UK / Ireland

More on GPs

EU foreign subsidies regulations
EU FSR could impact PE fundraising with potential rise in ‘clean funds’

FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely

  • Regulation
  • 01 September 2023
Jan Cerny of BHM Group
BHM Group builds on PE strategy, eyes European medtech and renewable energy acquisitions

Czech Republic-headquartered family office is targeting DACH and CEE region deals

  • Investments
  • 01 September 2023
Bettina Curtze of Redalpine
Redalpine expands leadership team amid CHF 1bn-plus fundraise

Ex-Rocket Internet leader Bettina Curtze joins Swiss VC firm as partner and CFO

  • Venture
  • 31 August 2023
Canary Wharf and the financial centre of London
IPO offers CVC chance to become multi-asset consolidator

Potential IPO also offers monetisation solution for founders and GP stakes investor Blue Owl

  • GPs
  • 25 August 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013